Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_aa61bdf2f122c63d8162822339e67792 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_649a15e6600ad9f8e38f1bc129fcab56 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ed28726de9f916f355f8adc331e736b8 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2500-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-5754 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-57536 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39558 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5011 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-74 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7088 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57407 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-74 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-575 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-17 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
filingDate |
2011-10-06^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate |
2013-12-03^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_976421c86258649a38badeddf7ab20ff http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_07b02301fe6abf6894d5c46433a684c3 |
publicationDate |
2013-12-03^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
US-8597645-B2 |
titleOfInvention |
Cancer treatment with endothelin receptor antagonists |
abstract |
The present invention relates to therapeutic protocols and pharmaceutical compositions designed to treat and prevent cancer. More specifically, the present invention relates to a novel method of treating cancer using antagonists to the endothelin B receptor (ETB) or inactive mimic forms of endothelin-1. The pharmaceutical compositions of the invention are capable of selectively inhibiting the early events associated with the development of cancer. The present invention further relates to screening assays to identify compounds which inhibit ETB activation. |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10639304-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2021309694-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9636340-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11338014-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11066442-B2 |
priorityDate |
1999-05-04^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |